The relevant Reuters story of this morning concludes by suggesting that, if Crestor's to-be-announced-March 30, 2009 trial (called "Aurora") for end stage renal disease patients (on dialysis) has failed, it would seem likely that Schering-Plough's SHARP study will also fail, when finished, in 2010. Who knows? But here is the snippet -- from the Reuters story -- related to Schering-Plough:
. . . .Anderson said failure in the Aurora [Crestor] study would not be surprising.
A previous trial called 4D, with Pfizer's Lipitor, also failed in a similar way and Anderson said. . . Schering-Plough's Vytorin could be the next to fail when results from the Sharp trial are released in 2010.
"Having penetrated more traditional cardiovascular patient populations, drug companies have pushed to find new patient populations -- like those with severe kidney disease -- for their products. The outer limits of who might benefit next may have been reached," he said. . . .